AbCellera Biologics (ABCL) to Release Earnings on Tuesday

AbCellera Biologics (NASDAQ:ABCL) is scheduled to be issuing its quarterly earnings data after the market closes on Tuesday, August 6th. Analysts expect the company to announce earnings of ($0.16) per share for the quarter. Investors that are interested in registering for the company’s conference call can do so using this link.

AbCellera Biologics (NASDAQ:ABCL) last released its earnings results on Tuesday, May 7th. The company reported ($0.14) EPS for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.02. AbCellera Biologics had a negative return on equity of 12.61% and a negative net margin of 410.47%. The company had revenue of $9.95 million during the quarter, compared to analysts’ expectations of $10.73 million. During the same quarter last year, the business posted ($0.14) EPS. The firm’s revenue for the quarter was down 18.4% compared to the same quarter last year. On average, analysts expect AbCellera Biologics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

AbCellera Biologics Trading Down 4.3 %

Shares of ABCL stock opened at $2.92 on Monday. The company’s fifty day moving average price is $3.21 and its 200-day moving average price is $4.09. The stock has a market cap of $858.64 million, a PE ratio of -5.62 and a beta of 0.39. AbCellera Biologics has a 12 month low of $2.65 and a 12 month high of $7.10.

Analysts Set New Price Targets

Separately, KeyCorp reissued an “overweight” rating and set a $5.00 price objective (down previously from $7.00) on shares of AbCellera Biologics in a research note on Thursday, July 11th. Six investment analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $14.20.

AbCellera Biologics Company Profile

AbCellera Biologics Inc builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis.